PT - JOURNAL ARTICLE AU - Bowie, Cam AU - Friston, Karl TI - A twelve-month projection to September 2022 of the Covid-19 epidemic in the UK using a Dynamic Causal Model AID - 10.1101/2021.10.04.21262827 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.04.21262827 4099 - http://medrxiv.org/content/early/2021/10/07/2021.10.04.21262827.short 4100 - http://medrxiv.org/content/early/2021/10/07/2021.10.04.21262827.full AB - Objectives Predicting the future UK Covid-19 epidemic allows other countries to compare their epidemic with one unfolding without public health measures except a vaccine programme.Methods A Dynamic Causal Model (DCM) is used to estimate the model parameters of the epidemic such as vaccine effectiveness and increased transmissibility of alpha and delta variants, the vaccine programme roll-out and changes in contact rates. The model predicts the future trends in infections, long-Covid, hospital admissions and deaths.Results Two dose vaccination given to 66% of the UK population prevents transmission following infection by 44%, serious illness by 86% and death by 93%. Despite this, with no other public health measures used, cases will increase from 37 million to 61 million, hospital admission from 536,000 to 684,000 and deaths from 136,000 to 142,000 over twelve months.Discussion Vaccination alone will not control the epidemic. Relaxation of mitigating public health measures carries several risks – overwhelming the health services, the creation of vaccine resistant variants and the economic cost of huge numbers of acute and chronic cases.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.fil.ion.ucl.ac.uk/spm/covid-19/ Funding StatementCB is unfunded. KF is supported by Wellcome through core funding to the Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology [203147]. No third party payments sought or received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not required as all data used in the public domain.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDCM Covid-19 model available. Data used referenced and freely available on government websites. https://www.fil.ion.ucl.ac.uk/spm/covid-19/ https://www.dropbox.com/sh/brf5oehf5zcyul6/AACBNbLe-Gcg-YeTqiGzisKha?dl=0